getty On 19 February 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) dealt a serious blow to China’s “me-too” drug-makers hoping that China-derived data will grant them access to the US mark...
getty On 19 February 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) dealt a serious blow to China’s “me-too” drug-makers hoping that China-derived data will grant them access to the US mark...